MedPath

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Phase 1
Recruiting
Conditions
Advanced Lung Cancer
Interventions
Registration Number
NCT06892548
Lead Sponsor
BioNTech SE
Brief Summary

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).

Detailed Description

This is a two-part study designed to evaluate and establish two safe combination dose levels (recommended Phase 2 dose \[RP2D\] and a lower/another combination dose level \[RP2D-1\]) of BNT324 with BNT327 (Part 1), to determine the optimal combination dose (dose optimization \[DO\]) in NSCLC and SCLC lead indication cohorts at the RP2D and RP2D-1, to evaluate the preliminary efficacy in selected lung cancer cohorts at the highest combination dose level (in a signal seeking Part 2), and to confirm the clinical efficacy of BNT324 in combination with BNT327 at the optimal dose level in participants with advanced lung cancer in expansion cohorts (proof-of-concept \[POC\] cohorts).

The study consists of a screening period, a treatment period, a safety follow-up period, and a long-term survival follow-up period.

In Part 1 participants with histologically or cytologically confirmed relapsed or progressive lung cancer (both SCLC and NSCLC are eligible) will receive BNT324 in combination with BNT327 using a dose escalation design.

In Part 2 of the study, BNT324 will be studied in combination with BNT327 at the RP2D compared to RP2D-1 in participants with advanced metastatic treatment-naïve NSCLC (DO Cohort 1) and relapsed/progressive SCLC after failure of cytotoxic chemotherapy with or without immuno-oncology (IO) (DO Cohort 2). The totality of the available data (e.g., safety, efficacy, pharmacokinetics etc.) will be reviewed to select the optimal dose. After the optimal dose is selected, additional participants in each cohort may be enrolled in the selected optimal dose.

In the signal seeking cohorts (Cohort 3-7), participants will receive BNT324 in combination with BNT327 at the RP2D from Part 1.

A predefined number of participants in Part 2 Cohort 1 and Cohort 2 will be randomized to one of the two dose levels (RP2D and RP2D-1) selected from Part 1 in a 1:1 ratio. Additional participants in Part 2 Cohort 1 and Cohort 2 may be enrolled in the selected optimal dose to further assess the efficacy and safety profile.

No randomization is planned for any other cohort in Part 2 or Part 1.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
594
Inclusion Criteria
  • Aged ≥18 years at the time of giving informed consent.

  • Histological or cytological confirmed unresectable advanced/metastatic lung cancer. Histological classification may be based on tumor samples prior to metastatic disease. Participants with mixed histology must be classified based on the main component. Participants with NSCLC are eligible with any or no PD-L1 expression. Participants with AGA-positive disease must have received targeted therapy prior to enrollment in this study.

    • Part 1: Participants with NSCLC and SCLC
    • Part 2 Cohort 1: Participants with NSCLC (subpopulation 1) AGA negative, 1L
    • Part 2 Cohort 2: Participants with SCLC, 2L+
    • Part 2 Cohort 3: Participants with NSCLC (subpopulation 1) AGA negative, 2L+
    • Part 2 Cohort 4: Participants with NSCLC (subpopulation 2) AGA negative, 1L
    • Part 2 Cohort 5: Participants with NSCLC (subpopulation 2) AGA negative, 2L+
    • Part 2 Cohort 6: Participants with NSCLC AGA positive
    • Part 2 Cohort 7: Participants with SCLC, 1L
  • Have measurable disease defined by RECIST version 1.1.

  • Have an Eastern Cooperative Oncology Group performance status of 0 or 1.

  • Have a life expectancy of ≥12 weeks.

Exclusion Criteria
  • Prior treatment with B7-H3 targeted therapy.
  • Prior treatment with ADC with topoisomerase inhibitor (e.g., datopotamab deruxtecan, trastuzumab deruxtecan). Note: This exclusion applies to participants in the first-line/treatment-naïve cohorts in the advanced/metastatic setting. Prior treatment with ADC with topoisomerase inhibitor payload is only allowed for participants in the second-line plus cohorts in the advanced/metastatic setting.
  • Is a candidate to locoregional treatment (including surgical resection, stereotactic radiotherapy or tumor ablation) with potential to induce complete or near complete response and prolonged tumor control (sometimes described as "radical" intent), per investigator's assessment.
  • Has a history of significant hematologic toxicity to prior lines of therapy, as assessed by investigator, e.g., Grade 4 febrile neutropenia or recurrent/persistent Grade 3 to 4 neutropenia.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply to all or some participants depending on the cohort.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Part 1 - BNT324 + BNT327 combination therapyBNT324Escalating combination dose levels of BNT324 and BNT327 to define RP2D and RP2D-1 for NSCLC and SCLC.
Part 1 - BNT324 + BNT327 combination therapyBNT327Escalating combination dose levels of BNT324 and BNT327 to define RP2D and RP2D-1 for NSCLC and SCLC.
Part 2 - Cohort 1: RP2D of BNT324 + BNT327 and RP2D-1 of BNT324 + BNT327BNT324In subpopulation 1 of NSCLC actionable oncogenic alteration (AGA) negative, first-line (1L)
Part 2 - Cohort 1: RP2D of BNT324 + BNT327 and RP2D-1 of BNT324 + BNT327BNT327In subpopulation 1 of NSCLC actionable oncogenic alteration (AGA) negative, first-line (1L)
Part 2 - Cohort 2: RP2D of BNT324 + BNT327 and RP2D-1 of BNT324 + BNT327BNT324In SCLC, second-line plus (2L+)
Part 2 - Cohort 2: RP2D of BNT324 + BNT327 and RP2D-1 of BNT324 + BNT327BNT327In SCLC, second-line plus (2L+)
Part 2 - Cohort 3: RP2D of BNT324 + BNT327BNT324In subpopulation 1 of NSCLC AGA negative, 2L+
Part 2 - Cohort 3: RP2D of BNT324 + BNT327BNT327In subpopulation 1 of NSCLC AGA negative, 2L+
Part 2 - Cohort 4: RP2D of BNT324 + BNT327BNT324In subpopulation 2 of NSCLC AGA negative, 1L
Part 2 - Cohort 4: RP2D of BNT324 + BNT327BNT327In subpopulation 2 of NSCLC AGA negative, 1L
Part 2 - Cohort 5: RP2D of BNT324 + BNT327BNT324In subpopulation 2 of NSCLC AGA negative, 2L+
Part 2 - Cohort 5: RP2D of BNT324 + BNT327BNT327In subpopulation 2 of NSCLC AGA negative, 2L+
Part 2 - Cohort 7: RP2D of BNT324 + BNT327BNT324In SCLC, 1L
Part 2 - Cohort 6: RP2D of BNT324 + BNT327BNT324In NSCLC AGA positive
Part 2 - Cohort 6: RP2D of BNT324 + BNT327BNT327In NSCLC AGA positive
Part 2 - Cohort 7: RP2D of BNT324 + BNT327BNT327In SCLC, 1L
Primary Outcome Measures
NameTimeMethod
Part 1 - Occurrence of dose limiting toxicities (DLTs) by dose levelDuring the DLT evaluation period, i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days]
Part 1 - Occurrence of Treatment-emergent adverse events (TEAEs), serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by dose levelFrom the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
Part 1 - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs by dose levelFrom the time of the first dose of IMP to 90 days after the last dose of IMP or until new anticancer therapy is started, whichever occurs first
Part 2 cohorts 1 and 2 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment armFrom the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
Part 2 cohorts 1 and 2 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment armFrom the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
Part 2 cohorts 1 and 2 - Objective response rate (ORR) by cohort and treatment armFrom the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

ORR defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response (per response evaluation criteria in solid tumors \[RECIST\] version 1.1 based on the investigator's assessment).

Part 2 cohorts 3-7 - ORR by cohortFrom the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per RECIST version 1.1 based on the investigator's assessment).

Secondary Outcome Measures
NameTimeMethod
Part 1 - ORR by dose levelFrom the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per RECIST version 1.1 based on the investigator's assessment).

Part 1 - Disease control rate (DCR) by dose levelFrom the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

DCR, defined as the proportion of participants with confirmed CR, PR, or stable disease (SD) as best overall response (per RECIST version 1.1 based on the investigator's assessment).

Part 2 all cohorts - (PFS) by cohort and treatment armFrom the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

PFS defined as the time from first dose of IMP to the first objective tumor progression (PD) or death from any cause, whichever occurs first, per RECIST version 1.1 based on the investigator's assessment.

Part 2 all cohorts - Duration of response (DOR) by cohort and treatment armFrom the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

DOR, defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (PD) or death from any cause, whichever occurs first (per RECIST version 1.1 based on the investigator's assessment).

Part 2 all cohorts - Overall survival (OS) by cohort and treatment armFrom the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

OS, defined as the time from first dose of IMP to death from any cause.

Part 2 all cohorts - DCR by cohort and treatment armFrom the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

DCR, defined as the proportion of participants with confirmed CR, PR, or SD as best overall response (per RECIST version 1.1 based on the investigator's assessment).

Part 2 all cohorts - Time to response (TTR) by cohort and treatment armFrom the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

TTR, defined as the time from first dose of IMP to first objective response (CR or PR per RECIST version 1.1 based on the investigator's assessment).

Part 2 cohorts 3-7 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment armFrom the time of the first dose of IMPs to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first
Part 2 cohorts 3-7 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment armFrom the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first

Trial Locations

Locations (1)

Virginia Cancer Specialists

🇺🇸

Fairfax, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath